Patients with colorectal cancer who engaged in even low-intensity exercise while undergoing chemotherapy had increased progression-free survival with fewer side effects from therapy.
- First study to examine the association of physical activity with patient survival in advanced, metastatic colorectal cancer
- Even low-intensity exercise was associated with a reduction in progression free survival
Triple-targeted Therapy Benefits Advanced Colorectal Cancer Patients
In patients with BRAF-mutated metastatic colorectal cancer (mCRC), the three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival.
Advertisement
‘Moderate exercise such as walking four or more hours a week,was associated with a 20 percent reduction in colorectal cancer progression or mortality over the six-year study.’
Read More..
Tweet it Now
Read More..
Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.
Even low-intensity exercise, such as walking four or more hours a week, was associated with a nearly 20 percent reduction in cancer progression or death over the course of the six-year study, said researchers from Dana-Farber Cancer Institute and Brigham and Women's Hospital, reporting in the Journal of Clinical Oncology. The analysis hinted at a possible lengthening of survival in patients who reported greater physical activity, but the data were not statistically significant.
![Microbiome Changes Linked to Colorectal Cancer Detection]( "Microbiome Changes Linked to Colorectal Cancer Detection")
Colorectal cancer is linked to an increase in certain factors in the gut microbiome, as well as the presence of cancer-associated organisms, said new study.
"What we found was that people who engaged in some type of physical activity had a statistically significant improvement in progression-free survival (PFS)," said Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber, senior author of the study. "While there may also be an impact on overall survival, it was not statistically significant - and should be studied further."
"Physically active patients in our study also appeared to tolerate chemotherapy better," said Brendan Guercio, MD, first author of the study which was conducted while he was working as a hospitalist at Brigham and Women's. "Total physical activity equivalent to 30 or more minutes of moderate daily activity was associated with a 27 percent reduction in severe treatment-related toxicities."
Previous studies have found that regular exercise can reduce the risk of disease recurrence and death from colon cancer that has not metastasized to other parts of the body. Researchers say this is the first study to examine associations of physical activity with survival in advanced, metastatic colorectal cancer. Patients participated in a phase 3 study of chemotherapy for advanced colorectal cancer conducted by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute. Within a month after beginning treatment, patients were invited to complete a questionnaire about their average physical activity over the previous two months. The final number of participants included 1,218 patients. While the data are significant, further research with a randomized prospective trial will help validate the results, the researchers said.
Based on the patients' descriptions, researchers quantified their physical activity in terms of metabolic equivalent task (MET)-hours per week - a standard measure used in research studies of exercise. Vigorous activity was defined as any activity requiring six or more METs, such as running, biking, tennis, skiing, or lap swimming. Non-vigorous activities included walking, climbing stairs, or yoga.
Analysis of the data revealed a statistically significant difference in PFS - the length of time after the patient completed the questionnaire before the cancer progressed or the person died. The difference in PFS was almost 20 percent in favor of those who exercised more.
Meyerhardt added that the findings "help justify encouraging patients to exercise and referring patients to physical therapists or programs like the YMCA LIVESTRONG program that does small group training for patients with cancer."
The analysis also found that patients who engaged in 18 or more MET-hours per week of activity had a 15 percent improvement in overall survival (death from any cause) than patients who engaged in less than three MET-hours per week of activity. However, that difference was not statistically significant, meaning it could have resulted from chance.
Source: Eurekalert
Microbiome Changes Linked to Colorectal Cancer Detection
Colorectal cancer is linked to an increase in certain factors in the gut microbiome, as well as the presence of cancer-associated organisms, said new study.
Advertisement
"What we found was that people who engaged in some type of physical activity had a statistically significant improvement in progression-free survival (PFS)," said Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber, senior author of the study. "While there may also be an impact on overall survival, it was not statistically significant - and should be studied further."
"Physically active patients in our study also appeared to tolerate chemotherapy better," said Brendan Guercio, MD, first author of the study which was conducted while he was working as a hospitalist at Brigham and Women's. "Total physical activity equivalent to 30 or more minutes of moderate daily activity was associated with a 27 percent reduction in severe treatment-related toxicities."
Previous studies have found that regular exercise can reduce the risk of disease recurrence and death from colon cancer that has not metastasized to other parts of the body. Researchers say this is the first study to examine associations of physical activity with survival in advanced, metastatic colorectal cancer. Patients participated in a phase 3 study of chemotherapy for advanced colorectal cancer conducted by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute. Within a month after beginning treatment, patients were invited to complete a questionnaire about their average physical activity over the previous two months. The final number of participants included 1,218 patients. While the data are significant, further research with a randomized prospective trial will help validate the results, the researchers said.
Based on the patients' descriptions, researchers quantified their physical activity in terms of metabolic equivalent task (MET)-hours per week - a standard measure used in research studies of exercise. Vigorous activity was defined as any activity requiring six or more METs, such as running, biking, tennis, skiing, or lap swimming. Non-vigorous activities included walking, climbing stairs, or yoga.
Analysis of the data revealed a statistically significant difference in PFS - the length of time after the patient completed the questionnaire before the cancer progressed or the person died. The difference in PFS was almost 20 percent in favor of those who exercised more.
Meyerhardt added that the findings "help justify encouraging patients to exercise and referring patients to physical therapists or programs like the YMCA LIVESTRONG program that does small group training for patients with cancer."
The analysis also found that patients who engaged in 18 or more MET-hours per week of activity had a 15 percent improvement in overall survival (death from any cause) than patients who engaged in less than three MET-hours per week of activity. However, that difference was not statistically significant, meaning it could have resulted from chance.
Source: Eurekalert
Early-onset Colorectal Cancer is Rising at Alarming Rates in the West
Early-onset colorectal cancer (CRC) is rising most rapidly in Western states, reveals a new study.
Advertisement
 Cancer Drugs Promote Therapy Resistant Colorectal CancerScientists discovered that a certain group of cancer drugs activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.
Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.
In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.